Strides gets USFDA nod for Lamivudine and Zidovudine tabs
Health regulator US FDA (United States Food & Drug Administration) has given Abbreviated New Drug Application(ANDA)permission to Strides Arcolab to manufacture and market Lamivudine and Zidovudine tablets USP, 150mg/ 300mg.
Lamivudine and Zidovudine tablets are the group of antiretroviral medicines used to reduce amount of HIV levels in adults and children.
Lamivudine and Zidovudine tablets have a market of $120 million in US as per IMS data.
The firm will manufacture these products at its oral dosage facility at Bangalore and marketed by strides in US and will be launched immediately.